Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness
Jonathan Hamill, Jaime E. C. Hallak, Serdar Dursun, et al.
Current Neuropharmacology (2018) Vol. 17, Iss. 2, pp. 108-128
Open Access | Times Cited: 144

Showing 1-25 of 144 citing articles:

Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 163
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Joost J. Breeksema, Bouwe Kuin, Jeanine Kamphuis, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 10, pp. 1100-1117
Open Access | Times Cited: 130
Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects
Helena D. Aicher, Michael J. Mueller, Dario A. Dornbierer, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 16
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research
Roger S. McIntyre, Angela T.H. Kwan, Rodrigo B. Mansur, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 21-32
Closed Access | Times Cited: 2
The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials
Lavinia Hogea, Dana Cătălina Tabugan, Iuliana Costea, et al.
Medicina (2025) Vol. 61, Iss. 2, pp. 278-278
Open Access | Times Cited: 2
Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact
Andreia Machado Brito-da-Costa, Diana Dias da Silva, Nelson G. M. Gomes, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 11, pp. 334-334
Open Access | Times Cited: 86
Effects of DMT on mental health outcomes in healthy volunteers
Christopher Timmermann, Richard J. Zeifman, David Erritzøe, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 15
N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk
Dan Cheng, Zhuogui Lei, Kin Chu, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 14
New and emerging treatments for major depressive disorder
Cecilia Njenga, Parashar Pravin Ramanuj, Frederico Jose Coelho de Magalhães, et al.
BMJ (2024), pp. e073823-e073823
Closed Access | Times Cited: 11
The Production of Entheogenic Communities in the United States
Brad Stoddard
(2024)
Closed Access | Times Cited: 9
The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial
Richard J. Zeifman, Fernanda Palhano-Fontes, Jaime E. C. Hallak, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 64
Exploring the case for research on incorporating psychedelics within interventions for borderline personality disorder
Richard J. Zeifman, Anne Catherine Wagner
Journal of Contextual Behavioral Science (2019) Vol. 15, pp. 1-11
Closed Access | Times Cited: 61
Rapid-acting antidepressants
Jeffrey M. Witkin, Anna Martin, Lalit K. Golani, et al.
Advances in pharmacology (2019), pp. 47-96
Closed Access | Times Cited: 61
Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial
Richard J. Zeifman, Nikhita Singhal, Rafael G. dos Santos, et al.
Psychopharmacology (2020) Vol. 238, Iss. 2, pp. 453-459
Closed Access | Times Cited: 61
From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders
Urszula Kozłowska, Charles D. Nichols, Kalina Wiatr, et al.
Journal of Neurochemistry (2021) Vol. 162, Iss. 1, pp. 89-108
Open Access | Times Cited: 54
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
Joseph M. Rootman, Pamela Kryskow, Kalin Harvey, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 53
On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review
Richard J. Zeifman, Nikhita Singhal, Leah Breslow, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 436-451
Open Access | Times Cited: 47
Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors
Klemens Egger, Helena D. Aicher, Paul Cumming, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 6
Toxicity of ayahuasca after 28 days daily exposure and effects on monoamines and brain-derived neurotrophic factor (BDNF) in brain of Wistar rats
Camila Schoueri Colaço, Stefany Sousa Alves, Luciana Marangni Nolli, et al.
Metabolic Brain Disease (2020) Vol. 35, Iss. 5, pp. 739-751
Closed Access | Times Cited: 48
Ayahuasca's therapeutic potential: What we know – and what not
Lucas Oliveira Maia, Dimitri Daldegan‐Bueno, Isabel Wießner, et al.
European Neuropsychopharmacology (2022) Vol. 66, pp. 45-61
Closed Access | Times Cited: 28
Analysis of recreational psychedelic substance use experiences classified by substance
Adrian Hase, M Erdmann, Verena Limbach, et al.
Psychopharmacology (2022) Vol. 239, Iss. 2, pp. 643-659
Open Access | Times Cited: 25
Ayahuasca: A review of historical, pharmacological, and therapeutic aspects
Simon Ruffell, Max Crosland‐Wood, Rob Palmer, et al.
Psychiatry and Clinical Neurosciences Reports (2023) Vol. 2, Iss. 4
Open Access | Times Cited: 15
Therapeutics to Treat Psychiatric and Neurological Disorders: A Promising Perspective from Algerian Traditional Medicine
Farida Larit, Francisco León
Plants (2023) Vol. 12, Iss. 22, pp. 3860-3860
Open Access | Times Cited: 13
Biomedical analysis of New Psychoactive Substances (NPS) of natural origin
Alfredo Fabrizio Lo Faro, Annagiulia Di Trana, Nunzia La Maida, et al.
Journal of Pharmaceutical and Biomedical Analysis (2019) Vol. 179, pp. 112945-112945
Closed Access | Times Cited: 41
Rapid-Acting Antidepressants
Jeffrey M. Witkin, Daniel E. Knutson, Gabriel J. Rodriguez, et al.
Current Pharmaceutical Design (2018) Vol. 24, Iss. 22, pp. 2556-2563
Closed Access | Times Cited: 39
Page 1 - Next Page

Scroll to top